Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Phase 2 Completed 106 enrolled Fujian Medical University

RandomizedParallel-groupOpen-labelTreatment

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	—
Subject	Rivoceranib	Small molecule	250 mg	Oral
Background	Paclitaxel	Small molecule	125 mg/m2	—
Background	S-1	Small molecule	40 mg	Oral
Background	S-1	Small molecule	50 mg	Oral
Background	S-1	Small molecule	60 mg	Oral